Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene

被引：49

作者：

Tonini, G.

Bizzarri, C.

Bonfanti, R.

Vanelli, M.

Cerutti, F.

Faleschini, E.

Meschi, F.

Prisco, F.

Ciacco, E.

Cappa, M.

Torelli, C.

Cauvin, V.

Tumini, S.

Iafusco, D.

Barbetti, F. ^{[1
]}

机构：

[1] S Raffaele Biomed Pk Fdn, Rome, Italy

[2] Univ Roma Tor Vergata, Dept Internal Med, I-00173 Rome, Italy

[3] Univ Chieti, Dept Paediat, Chieti, Italy

[4] Santa Chiara Hosp, Dept Paediat, Trento, Italy

[5] Giovanni XXIII Hosp, Dept Paediat, Bari, Italy

[6] Childrens Inst IRCCS Burlo Garofolo, Dept Paediat, Trieste, Italy

[7] IRCCS, Bambino Gesu Childrens Hosp, Rome, Italy

[8] IRCCS, Hosp S Raffaele, Dept Paediat, Milan, Italy

[9] Univ Modena, Dept Paediat, I-41100 Modena, Italy

[10] Univ Turin, Dept Paediat, I-10124 Turin, Italy

[11] Univ Naples 2, Dept Paediat, Naples, Italy

来源：

DIABETOLOGIA | 2006年 / 49卷 / 09期

关键词：

GLIBENCLAMIDE; ATP;

D O I：

10.1007/s00125-006-0329-x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2210 / 2213

页数：4

共 10 条

[1] High-dose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation [J].

Codner, E ;

Flanagan, S ;

Ellard, S ;

García, H ;

Hattersley, AT .

DIABETES CARE, 2005, 28 (03) :758-759

[2] Transient neonatal diabetes mellitus is associated with a recurrent (R201H) KCNJ11 (KIR6.2) mutation [J].

Colombo, C ;

Delvecchio, M ;

Zecchino, C ;

Faienza, MF ;

Cavallo, L ;

Barbetti, F .

DIABETOLOGIA, 2005, 48 (11) :2439-2441

[3] Relapsing diabetes can result from moderately activating mutations in KCNJ11 [J].

Gloyn, AL ;

Reimann, F ;

Proks, P ;

Pearson, ER ;

Temple, IK ;

Mackay, DJG ;

Shield, JPH ;

Freedenberg, D ;

Noyes, K ;

Ellard, S ;

Ashcroft, FM ;

Gribble, FM ;

Hattersley, AT .

HUMAN MOLECULAR GENETICS, 2005, 14 (07) :925-934

[4] Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes [J].

Gloyn, AL ;

Pearson, ER ;

Antcliff, JF ;

Proks, P ;

Bruining, GJ ;

Slingerland, AS ;

Howard, N ;

Srinivasan, S ;

Silva, JMCL ;

Molnes, J ;

Edghill, EL ;

Frayling, TM ;

Temple, IK ;

Mackay, D ;

Shield, JPH ;

Sumnik, Z ;

van Rhijn, A ;

Wales, JKH ;

Clark, P ;

Gorman, S ;

Aisenberg, J ;

Ellard, S ;

Njolstad, PR ;

Ashcroft, FM ;

Hattersley, AT .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (18) :1838-1849

[5] Activating mutations in Kir6.2 and neonatal diabetes - New clinical syndromes, new scientific insights, and new therapy [J].

Hattersley, AT ;

Ashcroft, FM .

DIABETES, 2005, 54 (09) :2503-2513

[6] ATP and sulfonylurea sensitivity of mutant ATP-sensitive K+ channels in neonatal diabetes -: Implications for pharmacogenomic therapy [J].

Koster, JC ;

Remedi, MS ;

Dao, C ;

Nichols, CG .

DIABETES, 2005, 54 (09) :2645-2654

[7]

KUPLA T, 2005, DIABETOLOGIA, V48, P1029

[8] KCNJ11 activating mutations in Italian patients with permanent neonatal diabetes [J].

Massa, O ;

Iafusco, D ;

D'Amato, E ;

Gloyn, AL ;

Hattersley, AT ;

Pasquino, B ;

Tonini, G ;

Dammacco, F ;

Zanette, G ;

Meschi, F ;

Porzio, O ;

Bottazzo, G ;

Crinó, A ;

Lorini, R ;

Cerutti, F ;

Vanelli, M ;

Barbetti, F .

HUMAN MUTATION, 2005, 25 (01) :22-27

[9] Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2 -: Patient characteristics and initial response to sulfonylurea therapy [J].

Sagen, JV ;

Ræder, H ;

Hathout, E ;

Shehadeh, N ;

Gudmundsson, K ;

Bævre, H ;

Abuelo, D ;

Phornphutkul, C ;

Molnes, J ;

Bell, GI ;

Gloyn, AL ;

Hattersley, AT ;

Molven, A ;

Sovik, O ;

Njolstad, PR .

DIABETES, 2004, 53 (10) :2713-2718

[10] Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2 [J].

Zung, A ;

Glaser, B ;

Nimri, R ;

Zadik, Z .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (11) :5504-5507

← 1 →